Steroid 5-alpha reductase type II V89L substitution is not associated with risk of prostate cancer in a multiethnic population study.

Article Details

Citation

Pearce CL, Makridakis NM, Ross RK, Pike MC, Kolonel LN, Henderson BE, Reichardt JK

Steroid 5-alpha reductase type II V89L substitution is not associated with risk of prostate cancer in a multiethnic population study.

Cancer Epidemiol Biomarkers Prev. 2002 Apr;11(4):417-8.

PubMed ID
11927504 [ View in PubMed
]
Abstract

Not Available

DrugBank Data that Cites this Article

Polypeptides
NameUniProt ID
3-oxo-5-alpha-steroid 4-dehydrogenase 2P31213Details